Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis

Journal of the National Cancer Institute

Volumn 100, Issue 18, 2008, Pages 1331-1332

  Chlebowski, Rowan T ^a   Col, Nananda ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYTOCHROME P450 2D6; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIAZOLE DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTERY DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG METABOLISM; ENDOMETRIUM CANCER; GENE MUTATION; GENOTYPE; GYNECOLOGIC DISEASE; HEART INFARCTION; HIP FRACTURE; HUMAN; LETTER; LUNG EMBOLISM; MONOTHERAPY; OSTEOLYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; SIDE EFFECT; STROKE; VEIN DISEASE; ADJUVANT CHEMOTHERAPY; ASIAN; BREAST TUMOR; DECISION MAKING; DISEASE FREE SURVIVAL; ETHNOLOGY; FEMALE; GENETICS; MIDDLE AGED; MORTALITY; NOTE; PATIENT PARTICIPATION; POSTMENOPAUSE; STATISTICS; BONE DENSITY; DRUG EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; DECISION MAKING; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENOTYPE; HUMANS; MARKOV CHAINS; MIDDLE AGED; NITRILES; PATIENT PARTICIPATION; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS;

EID: 52449112936     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn272     Document Type: Letter

References (7)

1. Punglia RC, Burstein H, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008;100(9):642-648.
2. Coates A, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5A):486-492.
3. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists Group. Effects of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2007;9(1):45-53.
4. Chlebowski RT. Current options for breast cancer risk reduction. Menopause Manage. 2008;17(S1):20-24.
5. Hillner B, Ingle J, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update of the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057.
6. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526-532.
7. Rae JM, Sikora MJ, Henry MJ, et al. Cytochrome P450 2D6 activity predicts adherence to tamoxifen therapy. Breast Cancer Res Treat. 2007;106(suppl 1):521.